Výsledky vyhledávání

Akademický článek

Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors.

Autor: Kropp KN; Internal Medicine III, University Cancer Center (UCT), Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany., Fatho M; Internal Medicine III, University Cancer Center (UCT), Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany., Huduti E; Internal Medicine III, University Cancer Center (UCT), Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany., Faust M; Internal Medicine III, University Cancer Center (UCT), Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany., Lübcke S; Internal Medicine III, University Cancer Center (UCT), Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany., Lennerz V; Internal Medicine III, University Cancer Center (UCT), Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany., Paschen A; Dermatology, University Hospital, University Duisburg/Essen and German Cancer Research Consortium (DKTK), Partner Site Essen/Duesseldorf, Essen, Germany., Theobald M; Internal Medicine III, University Cancer Center (UCT), Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany., Wölfel T; Internal Medicine III, University Cancer Center (UCT), Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany., Wölfel C; Internal Medicine III, University Cancer Center (UCT), Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Oct 02; Vol. 14, pp. 1245559. Date of Electronic Publication: 2023 Oct 02 (Print Publication: 2023).

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma.

Autor: Chen, Xinyi¹ (AUTHOR) joanna.m.troka@kcl.ac.uk, Habib, Shabana¹ (AUTHOR) avigail.rahimi@kcl.ac.uk, Alexandru, Madalina¹ (AUTHOR) heather.bax@kcl.ac.uk, Chauhan, Jitesh¹ (AUTHOR), Evan, Theodore¹ (AUTHOR), Troka, Joanna M.¹ (AUTHOR), Rahimi, Avigail¹ (AUTHOR), Esapa, Benjamina¹ (AUTHOR), Tull, Thomas J.¹ (AUTHOR), Ng, Wen Zhe¹ (AUTHOR), Fitzpatrick, Amanda^1,2,3 (AUTHOR), Wu, Yin^1,3,4 (AUTHOR), Geh, Jenny L. C.^5,6 (AUTHOR), Lloyd-Hughes, Hawys⁶ (AUTHOR), Palhares, Lais C. G. F.¹ (AUTHOR), Adams, Rebecca¹ (AUTHOR), Bax, Heather J.¹ (AUTHOR), Whittaker, Sean¹ (AUTHOR), Jacków-Malinowska, Joanna¹ (AUTHOR), Karagiannis, Sophia N.^1,3 (AUTHOR) sophia.karagiannis@kcl.ac.uk

Publikováno v: Cancers. Oct2024, Vol. 16 Issue 19, p3260. 22p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Evolution of melanoma cross-resistance to CD8 ⁺ T cells and MAPK inhibition in the course of BRAFi treatment.

Autor: Pieper N; Department of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany., Zaremba A; Department of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany., Leonardelli S; Department of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany., Harbers FN; Department of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany., Schwamborn M; Department of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany., Lübcke S; Department of Internal Medicine III, University Medical Center, Johannes Gutenberg University, Mainz, Germany., Schrörs B; Department of Internal Medicine III, University Medical Center, Johannes Gutenberg University, Mainz, Germany., Baingo J; Department of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany., Schramm A; Molecular Oncology, Department of Internal Medicine, University Hospital Essen, Germany., Haferkamp S; Department of Dermatology, University Hospital Regensburg, Germany., Seifert U; Friedrich Loeffler Institute of Medical Microbiology, University Medicine Greifswald, Greifswald, Germany., Sucker A; Department of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany., Lennerz V; Department of Internal Medicine III, University Medical Center, Johannes Gutenberg University, Mainz, Germany., Wölfel T; Department of Internal Medicine III, University Medical Center, Johannes Gutenberg University, Mainz, Germany., Schadendorf D; Department of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany., Schilling B; Department of Dermatology, Venerology and Allergology, University Hospital Würzburg, Germany., Paschen A; Department of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany., Zhao F; Department of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany.

Publikováno v: Oncoimmunology [Oncoimmunology] 2018 Apr 18; Vol. 7 (8), pp. e1450127. Date of Electronic Publication: 2018 Apr 18 (Print Publication: 2018).

Zobrazit plný text záznamu

Akademický článek

HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.

Autor: Schrörs B; Internal Medicine III, University Cancer Center (UCT) and Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany., Lübcke S; Internal Medicine III, University Cancer Center (UCT) and Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany., Lennerz V; Internal Medicine III, University Cancer Center (UCT) and Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany., Fatho M; Internal Medicine III, University Cancer Center (UCT) and Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany., Bicker A; Institute for Molecular Genetics, Johannes Gutenberg University, Mainz, Germany., Wölfel C; Internal Medicine III, University Cancer Center (UCT) and Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany., Derigs P; Internal Medicine III, University Cancer Center (UCT) and Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany., Hankeln T; Institute for Molecular Genetics, Johannes Gutenberg University, Mainz, Germany., Schadendorf D; Department of Dermatology, University Hospital, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany., Paschen A; Department of Dermatology, University Hospital, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany., Wölfel T; Internal Medicine III, University Cancer Center (UCT) and Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany.

Publikováno v: Oncotarget [Oncotarget] 2017 Apr 25; Vol. 8 (17), pp. 28312-28327.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání